Name (Synonyms) | Correlation | |
---|---|---|
drug2874 | lulizumab pegol Wiki | 1.00 |
drug3031 | tocilizumab Wiki | 1.00 |
drug2813 | everolimus Wiki | 1.00 |
drug2904 | mycophenolate mofetil Wiki | 1.00 |
drug499 | CT-imaging Wiki | 1.00 |
drug2742 | antithymocyte globulin (rabbit) Wiki | 1.00 |
drug2755 | belatacept Wiki | 1.00 |
drug2890 | methylprednisolone Wiki | 1.00 |
drug1898 | Prednisone Wiki | 0.45 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The purpose of this study is to evaluate the safety of using lulizumab pegol with tocilizumab, belatacept, and everolimus in kidney transplant recipients.
Description: Definitions: Acute T cell Mediated Rejection: Biopsy proven rejection defined by histologic evidence of a Banff grade of ≥1A and clinical treatment for acute rejection. Acute Antibody Mediated Rejection: Diffusely positive immunostaining staining for C4d, presence of circulating anti-donor antibodies, and morphologic evidence of acute tissue injury. Reference: Banff 2007 Classification Renal Allograft Pathology definition of terms.
Measure: Proportion of participants who remain free of biopsy-proven acute T-cell mediated or antibody-mediated rejection as defined by Banff criteria Time: 6 months post transplantationDescription: Definitions: Acute T cell Mediated Rejection: Biopsy proven rejection defined by histologic evidence of a Banff grade of ≥1A and clinical treatment for acute rejection. Acute Antibody Mediated Rejection: Diffusely positive immunostaining staining for C4d, presence of circulating anti-donor antibodies, and morphologic evidence of acute tissue injury. Reference: Banff 2007 Classification Renal Allograft Pathology definition of terms.
Measure: Proportion of participants who remain free of biopsy-proven acute T-cell mediated or antibody-mediated rejection as defined by Banff criteria Time: 12 months post transplantationDescription: Mechanistic assay. Evaluation of the frequency of circulating Tregs over time.Exploratory goal: To advance understanding in mechanisms of tolerance.
Measure: EXPLORATORY: Frequency of circulating T Regulatory Cells (Tregs) Time: Day 0 (Pre-transplant) and -3, -6 and -12 months post transplantationDescription: Mechanistic assay.Donor-specific suppression activity of recipient Tregs will be measured over time by using irradiated donor peripheral blood mononuclear cells (PBMCs) as stimulators. Exploratory goal: To advance understanding in mechanisms of tolerance.
Measure: EXPLORATORY:T Regulatory Cells (Treg) suppressive activity Time: Day 0 (Pre-transplant) and -3, -6 and -12 months post transplantationDescription: Mechanistic assay that measures the frequency of circulating donor-reactive CD4 conventional T cells, CD8 T cells and Tregs analyzed over time. Exploratory goal: To advance understanding in mechanisms of tolerance.
Measure: EXPLORATORY:Alloreactive T cell frequency Time: Day 0 (Pre-transplant) and -3, -6 and -12 months post transplantationDescription: Methodology: Analysis of gene expression in peripheral blood mononuclear cells (PBMCs) stimulated with donor antigen presenting cells to explore genes implicated in T cell checkpoint inhibition (CTLA-4, SFASL, NFATC1, NFATC2, LAG3 and HAVCR2, as examples). Exploratory goal: To advance understanding in mechanisms of tolerance.
Measure: EXPLORATORY:Expression of T cell checkpoint inhibition related genes Time: Day 0 (Pre-transplant) and -3, -6 and -12 months post transplantation